EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...

The constant threat of recurrence feels like the proverbial sword of Damocles — always present, always waiting. If my cancer does return, the now-inert metal seeds scattered through my prostate and ...

编者按：2025年欧洲肿瘤内科学会（ESMO）年会将于10月17日~21日在德国柏林召开。作为肿瘤学界的年度盛典，ESMO每年都会吸引上万名世界各地的肿瘤学大咖，为全球学者提供了良好的交流平台。目前公布的摘要标题中，入选的中国泌尿肿瘤研究数量再创新高 ...

The European Commission has granted marketing authorization in the European Union (EU) for German pharma major Bayer’s Nubeqa ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

Berlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa ...

In patients with biochemical recurrence after prostate cancer surgery, the optimal duration of hormone therapy after salvage radiation therapy has been debated.

With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

European Union approves Bayer’s Nubeq for patients with advanced prostate cancer: Berlin Tuesday, July 22, 2025, 11:00 Hrs [IST] The European Commission has granted marketing au ...

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...